Abstract: A cyclic dinucleotide metal compound, and a preparation thereof are provided. The cyclic dinucleotide metal compound is represented by [M(cyclic dinucleotide)] or [M?2(cyclic dinucleotide)], where M is Mg2+, Zn2+, Mn2+ or Fe2+, and M? is Li+. The cyclic dinucleotide is 2?3?-cGAMP, c-di-AMP, c-di-GMP, c-di-IMP, c-GMP-IMP or a derivative thereof. Applications of the cyclic dinucleotide metal compound in the treatment of neurodegenerative diseases, ischemic cerebrovascular injuries and tumors are also provided.

Abstract: A liposome carrier-based multi-target complex, which includes a stimulator of interferon genes (STING) agonist, an immune checkpoint inhibitor, an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) inhibitor, and a liposome. The immune checkpoint inhibitor is configured to target at least two different immune checkpoints or antigenic epitopes. A weight ratio of the STING agonist to the ENPP1 inhibitor is 10:2.5-10, excluding 10:10, and a weight ratio of the STING agonist to the immune checkpoint inhibitor is 10:2.5-100, excluding 10:100. This application also provides a drug delivery platform and applications of the multi-target complex.

Abstract: A natural immune agonist complex, consisting of an immune agonist and a targeted liposome, where the immune agonist is M(cGAMP)Ln. The targeted liposome is formed by a nanobody targeting a tumor microenvironment, a cell membrane-targeted penetrating peptide, or a blood-brain barrier-targeted penetrating peptide with a liposome through chemical bonding. This application further provides a preparation and application of the natural immune agonist complex.

Abstract: The present invention belongs to the technical field of biomedicine, and discloses a multi-functional anti-tumor compound drug. A composition of the anti-tumor compound drug comprises an agonist of an innate immune pathway (STING) and an inhibitor of phosphodiesterase ENPP1. Both STING and ENPP1 are located on the endoplasmic reticulum membrane. An activator and the agonist of STING are hydrolysis substrates of ENPP1. The compound drug can have two-pronged effects. The compound anti-tumor drug has a better anti-tumor effect than that by using an innate immune agonist alone. Therefore, the innovative compound anti-tumor drug has an efficient clinical application prospect.

Abstract: The present invention belongs to the technical field of biomedicine, and discloses a novel anti-tumor compound. The anti-tumor compound is an immune activator cisplatin complex prepared from an innate immune pathway agonist and cisplatin drug molecules through a reaction. The anti-tumor drug has dual anti-tumor effects, achieves the two-pronged effects of activating innate immune pathways (generating immune T cells to fight tumors) and fighting tumors by a cisplatin chemotherapy drug, and has the significant effects of fighting tumors, increasing effect and decreasing toxicity as compared with the monofunctional cisplatin anticancer chemotherapy drug. Therefore, the novel immune activator cisplatin anti-tumor drug has an efficient clinical application prospect.

Abstract: The present disclosure provides a use based on Zn7MT3 or a derivative thereof. Zn7MT3 or a derivative thereof is used for prevention or treatment of Alzheimer's disease or other neurodegenerative diseases, or for development, screening or preparation of a medicament suitable for Alzheimer's disease or other neurodegenerative diseases. Further provided are a method for preparing Zn7MT3 and a method for preparing gH625-Zn7MT3. Zn7MT3 and the derivatives thereof of the present disclosure can be used for improving cognitive dysfunction of an AD brain, regulating the cellular morphology of hippocampus in the AD brain, inhibiting the deposition of the amyloid protein in the AD brain and inhibiting the apoptosis of nerve cells in the brain, and can effectively prevent the progression of senile dementia; and the method for preparing Zn7MT3 is simple and efficient, and gH625-Zn7MT3 can easily cross the blood-brain barrier.

Abstract: The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs.

Abstract: The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs.